Protocol Ledger

NCT05206370 · Phase III · COMPLETED

A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers

Interventional Phase III clinical trial protocol NCT05206370 sponsored by Achieve Life Sciences in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-01-20 Enrollment: 792 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05206370
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)792 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05206370
Protocol FieldVerified Registry Value
NCT IdentifierNCT05206370
Consolidated Lead SponsorAchieve Life Sciences
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment792 participants (ACTUAL)
Registered Start Date2022-01-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05206370
Hospital Research SiteLocationSite Profile
Jacksonville Center for Clinical ResearchJacksonville, FLOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI